[1] Ruiz-Cordero R, Devine WP. Targeted therapy and checkpoint immunotherapy in lung cancer[J].Surg Pathol Clin,2020,13(1):17-33. DOI:10.1016/j.path.2019.11.002.
[2] Hutchinson BD, Shroff GS, Truong MT, et al. Spectrum of lung adenocarcinoma[J].Semin Ultrasound CT MR,2019,40(3):255-264. DOI:10.1053/j.sult.2018.11.009.
[3] 解丙坤,彭文廷,孙长青,等. 肺癌囊泡征的CT表现与不同病理类型分析[J]. 国际医药卫生导报,2020,26(3):340-344. DOI:10.3760/cma.j.issn.1007-1245.2020.03.015.
[4] Qu Y, Cheng B, Shao N, et al. Prognostic value of immune-related genes in the tumor microenvironment of lung adenocarcinoma and lung squamous cell carcinoma[J].Aging (Albany NY),2020,12(6):4757-4777. DOI:10.18632/aging.102871.
[5] 王艳,张巍,宋园园. 不同病理类型周围型肺癌的螺旋CT特征及相关病理指标的差异分析[J]. 实用癌症杂志,2021,36(5):782-784. DOI:10.3969/j.issn.1001-5930. 2021. 05.023.
[6] Wang BY, Huang JY, Chen HC, et al. The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients[J].J Cancer Res Clin Oncol,2020,146(1):43-52. DOI:10.1007/s00432-019-03079-8.
[7] Xiufang T, Kun L, Jing W, et al. Effects of CT images at different reconstruction energies on radiotherapy planning of patients diagnosed with nonsmall cell lung cancer[J].J Cancer Res Ther,2021,17(5):1157-1164. DOI:10.4103/jcrt.jcrt_1030_21.
[8] 陆舜,虞永峰,纪文翔. 2015年肺癌诊疗指南:共识和争议[J]. 解放军医学杂志,2016,41(1):1-6. DOI:10.11855/j.issn.0577-7402.2016.01.01.
[9] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer,2009,45(2):228-247. DOI:10.1016/j.ejca.2008.10.026.
[10] 李琳,罗娅红. 一站式CT能谱联合灌注成像技术在肺癌病理类型鉴别中的应用研究[J]. 现代肿瘤医学,2021,29(6):1032-1035. DOI:10.3969/j.issn.1672-4992.2021.06.028.
[11] National Lung Screening Trial Research Team. Lung cancer incidence and mortality with extended follow-up in the national lung screening trial[J].J Thorac Oncol,2019,14(10):1732-1742. DOI:10.1016/j.jtho.2019.05.044.
[12] 胡蓉,徐耀,侯金鹏,等. 能谱CT多参数定量分析对鉴别肺癌病理类型的价值[J]. 实用放射学杂志,2019,35(3):464-468. DOI:10.3969/j.issn.1002-1671.2019.03.032.
[13] 王永丽,杨帆,刘文亚. 能谱CT多参数定量分析预测原发性肺癌病理类型[J]. 中国医学影像技术,2021,37(6):899-903. DOI:10.13929/j.issn.1003-3289.2021.06.025.
[14] 黄倩文,陈应东,钟华,等. 肺癌能谱CT相关参数定量与临床应用[J]. 临床放射学杂志,2020,39(7):1316-1321. DOI:10.13437/j.cnki.jcr.2020.07.017.
[15] 朱巧,任翠,张艳,等. 能谱CT成像评价晚期非小细胞肺癌化疗近期疗效的价值[J]. 放射学实践,2020,35(8):953-959. DOI:10.13609/j.cnki.1000-0313.2020.08.002.
[16] 陈艾,余飞,商亚军,等. 能谱CT碘基图在肺癌患者放化疗疗效评估中的应用价值[J]. 癌症进展,2021,19(10):1007-1010. DOI:10.11877/j.issn.1672-1535.2021. 19.10.08.
[17] 赵晓薇,潘自来,吴华伟. 能谱CT在中晚期肺癌疗效评估中的应用[J]. 放射学实践,2020,35(6):813-815. DOI:10.13609/j.cnki.1000-0313.2020.06.023.
[18] 于芹,陈进,夏茜,等. 双能光谱CT定量分析对肺腺癌化疗后疗效的评估价值[J]. 海南医学,2021,32(14):1846-1849. DOI:10.3969/j.issn.1003-6350.2021.14.021.
|